Search results for "loss"

showing 10 items of 2103 documents

2015

In order to minimize risks of pathogen transmission with the development of ecotourism in Gabon, a seasonal inventory has been performed in five contrasted biotopes in Ivindo (INP) and Moukalaba-Doudou (MDNP) National Parks. A total of 10,033 hematophagous flies were captured. The Glossinidae, with six different species identified, was the most abundant group and constitutes about 60% of the captured flies compared to the Stomoxys (6 species also identified) and Tabanidae with 28% and 12%, respectively. The Glossinidae showed a higher rate of capture in primary forest and in research camps. In INP, the Stomoxys showed a higher rate of capture in secondary forest and at village borders, wher…

Biotope0303 health sciencesgeographygeography.geographical_feature_categoryEcologyVeterinary (miscellaneous)030231 tropical medicineStomoxys15. Life on landBiologybiology.organism_classificationOld-growth forest030308 mycology & parasitologyGlossinidae03 medical and health sciences0302 clinical medicineInfectious DiseasesHabitatAbundance (ecology)Insect ScienceMuscidaeSecondary forestAnimal Science and ZoologyParasitologyParasite
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice

2021

Asperuloside is an iridoid glycoside found in many medicinal plants that has produced promising anti-obesity results in animal models. In previous studies, three months of asperuloside administration reduced food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD). However, the mechanisms by which asperuloside exerts its anti-obesity properties were not clarified. Here, we investigated homeostatic and nutrient-sensing mechanisms regulating food intake in mice consuming HFD. We confirmed the anti-obesity properties of asperuloside and, importantly, we identified some mechanisms that could be responsible for its therapeutic effect. Asperuloside reduced body weight …

Blood GlucoseLeptinMalecannabinoid (CB) receptor 10301 basic medicineTastePro-Opiomelanocortinfood intakeEndocrinology Diabetes and MetabolismAdipose tissueWeight Gainnutrient-sensing mechanismslcsh:Diseases of the endocrine glands. Clinical endocrinologyCyclopentane MonoterpenesEnergy homeostasisMiceEndocrinology0302 clinical medicineGlucosidesWeight lossInsulinasperuloside; cannabinoid (CB) receptor 1; CD36; FFAR1-4; food intake; nutrient-sensing mechanisms; TAS1R2-3; weight lossReceptorOriginal ResearchLeptindigestive oral and skin physiologyTaste PerceptionGhrelinTAS1R2-3Ghrelinmedicine.symptommedicine.medical_specialtyHypothalamusBiologyDiet High-Fatasperuloside03 medical and health sciencesInternal medicinemedicineAnimalsPyranslcsh:RC648-665Body WeightFFAR1-4030104 developmental biologyEndocrinologyAnti-Obesity Agentsweight lossEnergy IntakeCD36Weight gain030217 neurology & neurosurgery
researchProduct

Evidence for hypothalamic ketone bodies sensing: impact on food intake and peripheral metabolic responses in mice

2016

Monocarboxylates have been implicated in the control of energy homeostasis. Among them, the putative role of ketone bodies produced notably during high-fat diet (HFD) has not been thoroughly explored. In this study, we aimed to determine the impact of a specific rise in cerebral ketone bodies on food intake and energy homeostasis regulation. A carotid infusion of ketone bodies was performed on mice to stimulate sensitive brain areas for 6 or 12 h. At each time point, food intake and different markers of energy homeostasis were analyzed to reveal the consequences of cerebral increase in ketone body level detection. First, an increase in food intake appeared over a 12-h period of brain keton…

Blood GlucoseMale0301 basic medicineobesitynervous-systemPhysiology[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionEndocrinology Diabetes and MetabolismKetone BodiesEnergy homeostasisEatingMicebodiesHomeostasisGlucose homeostasisoxidative stressAgouti-Related ProteinNeuropeptide YPhosphorylationmonocarboxylate transporters2. Zero hunger[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]fat massHypothalamusKetone bodiesStarvation responseketogenic mediterranean dietweight-lossmedicine.medical_specialtybeta-hydroxybutyrateHypothalamusBiologyDiet High-Fat03 medical and health sciencesInsulin resistancerat-brainPhysiology (medical)Internal medicinemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Animalsglucose homeostasisAdenylate Kinase/metabolism; Agouti-Related Protein/metabolism; Animals; Blood Glucose; Diet High-Fat; Eating/drug effects; Eating/physiology; Energy Metabolism/drug effects; Energy Metabolism/physiology; Gluconeogenesis/drug effects; Gluconeogenesis/physiology; Homeostasis; Hypothalamus/drug effects; Hypothalamus/metabolism; Insulin Resistance/physiology; Ketone Bodies/pharmacology; Male; Mice; Mice Inbred C57BL; Neuropeptide Y/metabolism; Phosphorylation/drug effectsenergy homeostasisAdenylate KinaseGluconeogenesismedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyGluconeogenesislow-carbohydrateInsulin ResistanceEnergy Metabolism[SDV.AEN]Life Sciences [q-bio]/Food and NutritionHomeostasis
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome

2015

The impact of a natural supplement (Kepar; Rikrea, Italy), containing several plant extracts such as curcuma longa, silymarin, guggul, chlorogenic acid, and inulin, was evaluated in 78 patients with metabolic syndrome (MetS; 45 men; age: 62 ± 9 years). Kepar at a dose of 2 pills/d was given for 4 months as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study. Anthropometric variables, plasma lipids, glucose parameters, and oxidative stress were measured at baseline and after 4 months. We found significant reductions in body weight (from 81.1 ± 13.5 to 79.4 ± 12.5 kg, P < .0001), body mass index (from 29.6 [23.7] to 29.3 [21.9] kg/m2, P = .001), and wai…

Blood GlucoseMaleTime FactorssilymarinPilot Projectsmedicine.disease_causelaw.inventionchemistry.chemical_compoundlawWeight lossPlant GumsPlant GumCommiphoraCurcuma longainulinbiologyMetabolic Syndrome XMedicine (all)Middle AgedTreatment OutcomeItalyFemalemedicine.symptomCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyTime Factorchlorogenic acidmetabolic syndromePlant ExtractCurcumaChlorogenic acidguggulInternal medicineWeight LossmedicineHumansPilot ProjectCurcumaAgedDietary Supplementoxidative strePlants MedicinalPlant Extractsbusiness.industryCholesterolcholesterolBiomarkerbiology.organism_classificationmedicine.diseaseWeight LoOxidative Stressnatural supplementEndocrinologychemistryDietary SupplementsMetabolic syndromePhytotherapybusinessBody mass indexBiomarkersOxidative stressPhytotherapyAngiology
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct

Association between periodontal disease and non-fatal ischemic stroke: a case-control study

2014

This study aimed to investigate the association between clinical and radiological markers of periodontal disease and ischemic stroke and to assess the potential influence of inflammatory response on the observed associations.A prospective case-control study including a series of 48 cases with a minor ischemic stroke and 47 controls was conducted at the University Hospital of Dijon. Vascular risk factors, clinical dental examination (plaque index, gingival index, percentage of pockets5 mm, percentage of bleeding on probing (BOP) sites), dental panoramic (bone loss) and biological parameters (CRP, total cholesterol, HDL, LDL, fasting glucose) were collected. Conditional regression analyses we…

Blood GlucoseMalemedicine.medical_specialtyBleeding on probingAlveolar Bone LossBrain Ischemiachemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPeriodontal PocketProspective StudiesRisk factorProspective cohort studyGeneral DentistryStrokePeriodontal DiseasesAgedPeriodontitisDMF Indexbusiness.industryCholesterolCholesterol HDLDental Plaque IndexCase-control studyCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseDental Plaque IndexSurgeryStrokeC-Reactive ProteinCholesterolchemistryCase-Control StudiesHypertensionFemalePeriodontal Indexmedicine.symptombusinessBiomarkersActa Odontologica Scandinavica
researchProduct

Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One…

2018

OBJECTIVE The long-term impact of intentional weight loss on cardiovascular events remains unknown. We describe 12-month changes in body weight and cardiovascular risk factors in PREvención con DIeta MEDiterránea (PREDIMED)-Plus, a trial designed to evaluate the long-term effectiveness of an intensive weight loss lifestyle intervention on primary cardiovascular prevention. RESEARCH DESIGN AND METHODS Overweight/obese adults with metabolic syndrome aged 55–75 years (n = 626) were randomized to an intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet, physical activity promotion, and behavioral support (IG) or a control group (CG). The primary and seco…

Blood GlucoseMalemedicine.medical_specialtyMediterranean dietEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismOverweightDiet Mediterraneanlaw.inventionPrediabetic State03 medical and health sciences0302 clinical medicineRandomized controlled triallawWeight lossBehavior TherapyRisk FactorsDiabetes mellitusInternal medicineWeight LossInternal MedicineMedicineHumans030212 general & internal medicineObesityExercise physiologyExerciseLife StyleAgedCaloric RestrictionAdvanced and Specialized NursingMetabolic Syndromebusiness.industryLeptinMiddle AgedOverweightmedicine.diseaseExercise TherapyCardiovascular DiseasesFemalemedicine.symptomMetabolic syndromebusinessFollow-Up Studies
researchProduct

Association between chronic dental infection and acute myocardial infarction.

2008

Introduction: In patients with cardiovascular diseases several risk factors such as high blood pressure, diabetes, smoking and drinking habits, genetic disposition, and chronic inflammation must be considered. The aim of this study was to investigate whether there is a correlation between dental origin infections and the presence of an acutemyocardialinfarction(AMI).Methods:Atotalof125 patients who had experienced a myocardial infarction and 125healthyindividualswereincludedinthisstudy.Theoral examination was carried out following the consent of the ethics committee and the National Board for Radiation Protection and included the number of teeth, endodontically treated teeth, periodontal sc…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInfarctionDentistryDiabetes ComplicationsLeukocyte CountTooth LossSex FactorsRisk FactorsInternal medicineDiabetes mellitusPeriodontal Attachment LossmedicineTooth lossHumansPeriodontal PocketMyocardial infarctionObesityGeneral DentistryPeriodontal DiseasesAgedAged 80 and overTooth Nonvitalbiologybusiness.industryPeriapical DiseasesC-reactive proteinSmokingCase-control studyAge FactorsDental Pulp DiseasesMiddle Agedmedicine.diseaseRadiographyC-Reactive ProteinClinical attachment lossTooth DiseasesCase-Control StudiesChronic Diseasebiology.proteinMyocardial infarction complicationsFemalemedicine.symptomPeriodontal IndexbusinessGingival HemorrhageJournal of endodontics
researchProduct